Posted: February 24, 2017
The State of Montana joined the 26 other states, including Puerto Rico, that have now passed legislation to provide pathways for access to Biosimilars, and create much needed patient safety rules, including a guideline for pharmacists to communicate to physicians about a biosimilar substitution within 5 days of its dispensing. This communication strengthens the relationship between patient and physician, and allows physicians to track and counter events from these medications. CSRO would like to thank Representative Ron Ehli for bringing the significant legislation on behalf of Montana’s patients.
HB233 received unanimous approval from both Chambers before quickly being signed by the Governor. CSRO supported the safe introduction of interchangeable biologic drugs into the practice of medicine in Montana, and was a recorded proponent in Committee. Please continue to check the CSRO website for updates on many health care issues across the country.
